Search

everythinglearnresearchcommunity

for

Search:↓

PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.

A 24-year-old with hair thinning is using a regimen including dutasteride, RU58841, HGH, GHK-cu, and other compounds to protect and regrow hair. They are also incorporating a mild cutting cycle with testosterone propionate, anavar, and tirzepatide.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

A 21-year-old male is experiencing crown balding and is using RU58841, topical minoxidil, and plans to add dutasteride and oral minoxidil to his treatment. He seeks advice on increasing his treatment stack despite previous side effects like chest pain.

The user recommends a thickening clay as a great pre-styling product for hair volume and texture, despite its poor hold. They also mention using finasteride and express skepticism about the effectiveness of a shampoo containing saw palmetto and caffeine.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.

A user experienced significant hair shedding after 8 months of using oral dutasteride (0.5 mg), minoxidil (2.5 mg), and biotin (5 mg) daily. They are concerned about the effectiveness of the treatment and possible resistance to dutasteride.

Hair regrowth progress after two months using oral finasteride, oral minoxidil, biotin, and vitamins. Significant improvement with new hair growth and reduced shedding.

A 19-year-old with NW2-2.5 hair loss is starting finasteride soon, considering low dosages of 0.25mg daily or 0.5mg 3-5 times a week. They are also using derma stamping, ketoconazole shampoo, ACV washes, and various oils to maintain hair quality and reduce scalp itch.

Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.

A user who had success with finasteride for hair loss for 4-5 years experienced shedding after a 3-week break. They tried various treatments including different finasteride brands, dutasteride, topical treatments, and supplements, but are still facing hair loss.

The user feels hopeless about hair loss despite using finasteride, dutasteride, minoxidil, and RU58841, and having a hair transplant. They are advised to maintain consistency in treatment, consider increasing dutasteride dosage, and explore topical solutions for better results.

The user experienced severe hair shedding from months 10 to 14 but saw significant hair regrowth after continuing treatment with 1.2 mg finasteride and 3 mg minoxidil. They advise not to give up on medication despite initial setbacks.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

Pyrilutamide's long-term stability is uncertain, with potential degradation after 8-9 months if not stored properly. It's recommended to use fresh batches and store them in a cool, dark place.

The conversation discusses hair loss treatments, specifically the use of minoxidil, finasteride, and microneedling, and the experience of shedding hair as a potential sign of treatment effectiveness. Some users report positive results after initial shedding, while others express concerns about long-term hair loss and the effectiveness of treatments.

A 36-year-old is experiencing underwhelming results from derma stamping for hair thinning, using needle lengths of 0.5mm to 0.75mm. They are considering increasing needle length, taking a break, or pairing the treatment with rosemary oil.

A user is concerned about low testosterone while using finasteride 0.625mg MWF and considers ashwagandha for stress. Others suggest exercise, magnesium, and not worrying about testosterone levels if no significant side effects are felt.

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

The user is considering switching from a topical minoxidil and finasteride solution to oral minoxidil to improve hair growth, while maintaining oral finasteride. They are concerned about potential shedding and whether they can maintain any new growth.

KX-826 shows promise for hair maintenance at higher doses with minimal side effects, despite failing Phase III trials. The user believes it is more effective than Minoxidil, Finasteride, and RU58841.

The conversation discusses whether to try dutasteride for hair loss if finasteride had no effect. Users suggest dutasteride might be more effective as it is stronger and blocks more types of DHT.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

A 32-year-old user shared progress pictures after using finasteride for 12 months, starting with 0.25g for 5 months and then 0.5g for 7 months. They have not yet added minoxidil or dermarolling and will update at the one-year mark.

Dutasteride may reduce bone mineral density, but there's no increased risk of osteoporosis or fractures compared to finasteride. Users suggest resistance training to counter potential bone effects.

The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.